AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

KIORA PHARMACEUTICALS INC Director's Dealing 2021

Feb 3, 2021

35256_dirs_2021-02-03_44ff0a6c-8dd5-4fd5-9b00-a21cc5974451.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: EYEGATE PHARMACEUTICALS INC (EYEG)
CIK: 0001372514
Period of Report: 2021-02-01

Reporting Person: Obermayr Franz (Acting CEO)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	101613	Direct

Footnotes

F1: Received by the Reporting Person in connection with the acquisition by the issuer of all of the outstanding securities of Panoptes Pharma Ges.m.b.H on December 18, 2020.